Immix Biopharma Target Price

See Immix Biopharma's analyst price targets ($23) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$11.7

Average Target Price

$23.33

99.4% upside

3 analysts in the last 4 months

High: $26 | Low: $19

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-15	Mizuho Securities	$26	122.2% upside
2026-08-11	Morgan Stanley	$19	62.4% upside
2026-08-10	H.C. WainwrightRobert Burns	$25	113.7% upside
2026-05-22	H.C. WainwrightRobert Burns	$20	70.9% upside
2026-03-27	H.C. Wainwright	$15	28.2% upside
2026-02-09	Mizuho SecuritiesGraig Suvannavejh	$14	19.7% upside
2025-12-09	H.C. Wainwright	$12	2.6% upside
2024-07-01	H.C. WainwrightRobert Burns	$7	40.2% downside

Immix Biopharma (IMMX) FAQ

Immix Biopharma (IMMX) currently reports a target price of $23. Use the charts on this page to explore Immix Biopharma's target price history and peer comparisons.

Analysts' average 12-month price target for Immix Biopharma is $23, about 99.4% upside from the current share price of $11.7. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $23, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Immix Biopharma, and consider following IMMX for alerts when major investors trade the stock.